Adaptimmune Therapeutics PLC · OTC:ADAPY

Adaptimmune Therapeutics — Investor Presentation (October 2015)

32 slides from Adaptimmune Therapeutics's investor presentation, Oct 19, 2015

  1. Slide 1: Disclaimer

    Disclaimer This presentation contains “forward-looking statements,” as that term is defined under the Private Securities Litigation Reform Act of 1995 (PSLRA), which statements may be identified by words such as “believe,” “may”, “will,” “estimate,” “continue,” “anticipate,” “intend,” “expect” and o

  2. Slide 2: Investment Highlights

    Investment Highlights Focused on affinity enhanced T-cell therapies for autologous T-cell therapeutics to treat cancer Lead clinical candidate targeting NY-ESO T is in multiple human studies and has shown efficacy in solid tumors and hematologic cancer types Synovial sarcoma – 5 responses seen in fi

  3. Slide 3: TCR Platform built up over 15 years

    TCR Platform built up over 15 years 1999-2006 Avidex formed on basis of TCR technology from Oxford University Acquired by Medigene (2006) 2008 Adaptimmune formed as a virtual company with UPenn collaboration 2011-2014 Adaptimmune establishes R&D infrastructure and delivers promising clinical data 20

  4. Slide 4: Experienced Management Team and Board

    Experienced Management Team and Board Executive Management Name: Title: Experience: James Noble, MA, FCA CEO & Co-Founder Helen Tayton-Martin, PhD MBA COO & Co-Founder Adrian Rawcliffe CFO Rafael Amado, MD CMO Gwen Binder-Scholl, PhD EVP, Adaptimmune LLC Board of Directors Name: Affiliation: Experie

  5. Slide 5: TCRs recognize intracellular cancer antigens

    TCRs recognize intracellular cancer antigens The TCR is the natural mechanism for T-cells to distinguish a diseased cell from a healthy cell All proteins, including intracellular ones, are processed and presented as HLA-peptide complexes which are recognized by TCRs Many cancer targets are intracell

  6. Slide 6: Pipeline: Robust Pipeline of T-Cell Receptors

    NY-ESO TCR MAGE A10 TCR 12 Research Programs 20+ Validated Targets NSCLC Other solid tumors TCR Candidate Rights Research Pre-IND Phase 1/2 Comments First cohort completed. Two further cohorts enrolling 1st trial published in NMED 2nd trial (no auto SCT) in 2016 Continuing enrollment Initiating in 2

  7. Slide 7: Platform and Differentiation

    Platform and Differentiation

  8. Slide 8: Finding the Right Targets

    Finding the Right Targets Tumour cell Only low risk targets selected for TCR programs Over thirty validated targets and growing Engineered TCRs Safety Testing Robust Manufacturing Validated Targets Mass spectrometry Confirms surface expression and expression on tumor cells (i.e. not normal tissue)

  9. Slide 9: Finding the Right TCR Affinity

    Finding the Right TCR Affinity Safety Testing Robust Manufacturing Validated Targets Engineered TCRs Proprietary ability to make optimum engineered TCRs 1mM 100µM 10µM 1µM Individual TCRs in test panel Natural T cell Response – natural affinity TCR Adaptimmune engineered TCR T cell response Increasi

  10. Slide 10: Proprietary Safety Testing

    3D primary cultures and iCells Normal Primary Cell Screen Molecular Analysis Human Cell Testing Whole Blood Assay Allo-reactivity Screen “Core motif” identification Core motif genome search X-scan peptide mapping Redefined completely following two deaths on MAGE A3 study in 2011/12* *Linette et al,

  11. Slide 11: Proprietary Process for Manufacturing

    Proprietary Process for Manufacturing Leukapheresis Prepare patient with lymphodepletion Collection Infusion Natural T-cells isolated from patients Genes encoding enhanced TCR delivered to patient’s natural T-cells Lentiviral vector Enhanced T-cells expanded Exclusive license to DynaBeads® CD3/CD28

  12. Slide 12: Proprietary Process for Manufacturing

    Proprietary Process for Manufacturing Validated Targets | gp | Engineered TCRs | » | Safety Testing |» { Robust Manufacturing Leukapheresis Natural T-cells isolated from patients Genes encoding Engineered TCR enhanced TCR — delivered to patient's © lentiviral OOO: natural T-cells vector Vein to vein

  13. Slide 13: ADAP Phase I/II Study in Synovial Sarcoma

    ADAP Phase I/II Study in Synovial Sarcoma Generally incurable; 75% to 80% of patients do not survive past two to three years First line therapy: radiotherapy and chemotherapy, surgical resection where possible Study Design: Multicenter pilot study in 11 patients, objectives: Determine the response r

  14. Slide 14: Synovial Sarcoma: Encouraging Response Rate, Tolerability and Persistence

    Synovial Sarcoma Encouraging Response Rate, Tolerability and Persistence Of the first 11 patients, five responded: Only T-cell technology to show clinical anti-tumor response in a solid tumor Two non responders potentially under-dosed Two new cohorts initiated One cohort assessing low expressers, th

  15. Slide 15: Radiographic Pseudoprogression and Response of Lung Metastases

    ADAP Phase I/II Study in Synovial Sarcoma Radiographic Pseudoprogression and Response of Lung Metastases Baseline: Bilateral Miliary Metastatic disease Day +2: Pseudoprogression due to Immune Infilration Day +101: Complete Response Patient 201 NY-ESO C-Reactive Protein AACR April 2015

  16. Slide 16: Partial Response Followed by Tumor Resection in Sarcoma

    NY-ESO TCR T cells administered ADAP Phase I/II Study in Synovial Sarcoma Partial Response Followed by Tumor Resection in Sarcoma One month post NY-ESO TCR T cells Two months post NY-ESO T cells Source: Merchant, CTOS, 2014 ~ 70% reduction in lesion size at 2 months after administration of NY-ESO T-

  17. Slide 17: NY-ESO TCR T cells administered

    NY-ESO TCR T ‘One month ‘Two months cells post NY-ESO post NY-ESO T administered TCR T cells cells + ~ 70% reduction in lesion size at 2 months after administration of NY-ESO T-cells + The lesion was then deemed capable of resection Source: Merchant, CTOS, 2014

  18. Slide 18: ADAP Phase I/II Study in Multiple Myeloma Study Design

    ADAP Phase I/II Study in Multiple Myeloma Study Design US prevalence: 77,600 cases - approximately 27,000 new cases expected in 2015 Average five-year survival rates are estimated to be less than 45 percent Study Design: All enrolled patients (n=25) had symptomatic myeloma with active disease High r

  19. Slide 19: Compelling Response Rate Compared to Published Literature

    ADAP Phase I/II Study in Multiple Myeloma Compelling Response Rate Compared to Published Literature Two year overall survival (OS) and progression free survival (PFS) as of April 2015 16/25 patients remain alive; 8/25 remain in remission Median PFS = 19.1 months Median OS = 32.1 months 59 percent (1

  20. Slide 20: Encouraging Tolerability and Persistence

    ADAP Phase I/II Study in Multiple Myeloma Encouraging Tolerability and Persistence Generally well tolerated - all SAEs possibly related to the NY-ESO T-cells resolved No clinically apparent cytokine release syndrome despite high IL-6 levels CAR-Ts have been associated with severe adverse events attr

  21. Slide 21: ADAP Pipeline: Next Steps with NY-ESO

    Indication Research Pre-IND Phase 1/2 GSK option to license ADAP Pipeline: Next Steps with NY-ESO Cohort 1: High NY-ESO expression, 12 patients Synovial Sarcoma Cohort 2: Low NY-ESO expression, 10 patients Cohort 3: Removal of fludarabine, 10 patients Cohort 1: Autologous SCT, 25 patients. Data publ

  22. Slide 22: MAGE A10 Next proprietary target

    MAGE A10 Next proprietary target

  23. Slide 23: MAGE A10 – A multi-cancer target

    MAGE A10 expression from cancer genome atlas (TCGA) breast bladder lung head & neck melanoma ovarian NIH RAC March 2015 MAGE A10 – A multi-cancer target testis RNAseq (Log scale) GTEx Portal MAGE A10 expression is absent/low in most adult non-reproductive tissue tissues

  24. Slide 24: IND for MAGE A-10 TCR therapeutic filed

    IND for MAGE A-10 TCR therapeutic filed Preclinical testing complete NIH RAC approval obtained: March 10, 2015 IND approved: announced July 2, 2015 Initial trial in NSCLC expected to open in 2015 Basket study anticipated in 2016 in multiple cancers potentially including bladder, head and neck, breas

  25. Slide 25: ADAP Pipeline: Next Steps, Wholly-owned Targets

    MAGE-A10 TCR Indication Research Pre-IND Phase 1/2 ADAP Pipeline: Next Steps Wholly-owned ADAP Targets IND open Non-small cell lung cancer (NSCLC) Basket study: Solid tumors Safety testing ongoing; IND planned 1H16 Hepatocellular cancer 12 undisclosed cancer targets AFP TCR Research programs Adaptim

  26. Slide 26: ADAP Pipeline: Next Steps Wholly-owned ADAP Targets

    ADAP Pipeline: Next Steps Wholly-owned ADAP Targets =a MAGE-A10 TCR Ne small cell lung cancer (N: IND open Enrollment Q4 2015 Basket study: Solid tumors Enrollment in 2016 Generation 2 D IND 2017 EXER CoM Hepatocellular cancer Safety testing ongoing; IND planned 1H16 IND planned 1H 2106 Perey uae 12

  27. Slide 27: The GSK Strategic Collaboration

    The GSK Strategic Collaboration Announced June 2014: Up-front payment £25 million GSK has option to license NY-ESO at end of Phase 1/2 studies Adaptimmune conducts all clinical and non-clinical development work Enables Adaptimmune to optimize regulatory, vector, cell processing, analytical, automati

  28. Slide 28: Large un-partnered pipeline with ability to target almost all major tumors

    Large un-partnered pipeline with ability to target almost all major tumors Adaptimmune GSK 20+ Additional validated targets Twelve new targets selected for development Not yet nominated; programs with work ongoing are excluded Pool of 3: ADAP keeps 2 NY-ESO MAGE-A10 AFP 30+ validated therapeutic tar

  29. Slide 29: Key 2015/2016 Milestones YTD and Anticipated

    Key 2015/2016 Milestones YTD and Anticipated Q1 2015 Additions to Adaptimmune senior leadership team April 2015 AACR presented full cohort data for NY-ESO in Sarcoma and MM May 2015 IPO raises $176m net proceeds Q2 2015 Filing and acceptance of IND for Phase 1/2 studies for MAGE A-10 Q3 2015 Publica

  30. Slide 30: Adaptimmune summary

    Adaptimmune (NASDAQ: ADAP) Clinical stage biopharmaceutical company located in Oxfordshire, UK and Philadelphia, PA Developing engineered T-cell receptors (TCRs) to target cancer cells which the natural immune system cannot detect Highly differentiated among immuno-oncology peers due to proprietary

  31. Slide 31: Adaptimmune Engineered TCR T cell therapy Presentation Materials October 2015

    Adaptimmune Engineered TCR T cell therapy Presentation Materials October 2015

  32. Slide 32: Adaptimmune

    Adaptimmune Engineered TCR T cell therapy Presentation Materials October 2015 } Adaptimmune

Adaptimmune Therapeutics — Investor Presentation (October 2015) on 6ix